mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC
NCT05412589
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
35
Enrollment
OTHER
Sponsor class
Conditions
Stage III Hepatocellular Cancer (CNLC Staging)
Interventions
DRUG:
mFOLFOX7+Camrelizumab+Apatinib
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University